Literature DB >> 15454487

IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis.

Sharareh Emadi1, Denis Clay, Christophe Desterke, Bernadette Guerton, Eliane Maquarre, Agnès Charpentier, Claude Jasmin, Marie-Caroline Le Bousse-Kerdilès.   

Abstract

Myeloproliferation, myelofibrosis, and neoangiogenesis are the 3 major intrinsic pathophysiologic features of myeloid metaplasia with myelofibrosis (MMM). The myeloproliferation is characterized by an increased number of circulating CD34+ progenitors with the prominent amplification of dystrophic megakaryocytic (MK) cells and myeloid metaplasia in the spleen and liver. The various biologic activities of interleukin 8 (IL-8) in hematopoietic progenitor proliferation and mobilization as well as in neoangiogenesis prompted us to analyze its potential role in MMM. We showed that the level of IL-8 chemokine is significantly increased in the serum of patients and that various hematopoietic cells, including platelets, participate in its production. In vitro inhibition of autocrine IL-8 expressed by CD34+ cells with either a neutralizing or an antisense anti-IL-8 treatment increases the proliferation of MMM CD34(+)-derived cells and stimulates their MK differentiation. Moreover, addition of neutralizing anti-IL-8 receptor (CXC chemokine receptor 1 [CXCR1] or 2 [CXCR2]) antibodies to MMM CD34+ cells cultured under MK liquid culture conditions increases the proliferation and differentiation of MMM CD41+ MK cells and restores their polyploidization. Our results suggest that IL-8 and its receptors participate in the altered MK growth that features MMM and open new therapeutic prospects for this still incurable disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454487     DOI: 10.1182/blood-2003-12-4415

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

Review 1.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

Review 2.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

3.  IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Authors:  Carolina Schinke; Orsolya Giricz; Weijuan Li; Aditi Shastri; Shanisha Gordon; Laura Barreyro; Laura Barreryo; Tushar Bhagat; Sanchari Bhattacharyya; Nandini Ramachandra; Matthias Bartenstein; Andrea Pellagatti; Jacqueline Boultwood; Amittha Wickrema; Yiting Yu; Britta Will; Sheng Wei; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

4.  Expression analysis of primary mouse megakaryocyte differentiation and its application in identifying stage-specific molecular markers and a novel transcriptional target of NF-E2.

Authors:  Zhao Chen; Michael Hu; Ramesh A Shivdasani
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

Review 5.  JAK2 inhibitors: are they the solution?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-05-04

Review 6.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

Authors:  Julius Wehrle; Thalia S Seeger; Sven Schwemmers; Dietmar Pfeifer; Alla Bulashevska; Heike L Pahl
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

Review 8.  Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

9.  A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

Authors:  Dana N LeVine; Adam J Birkenheuer; Marjory B Brooks; Shila K Nordone; Dwight A Bellinger; Sam L Jones; Thomas H Fischer; Stephen E Oglesbee; Kahlina Frey; Nicole S Brinson; Allison P Peters; Henry S Marr; Alison Motsinger-Reif; Sif Gudbrandsdottir; James B Bussel; Nigel S Key
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

Review 10.  The Role of Megakaryocytes in Myelofibrosis.

Authors:  Johanna Melo-Cardenas; Anna Rita Migliaccio; John D Crispino
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-11       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.